ERBB2 and non-small cell lung carcinoma: For example, research revealed that EGFR was amplified and/or mutated in glioma and non-small-cell lung cancer [17], whereas ErbB2 was amplified in breast, ovarian and bladder cancer and in several other tumors [18, 19].